Ark Still Accumulating Novartis

Ark Still Accumulating Novartis

#Novartis’s pipeline is deep and should give potential investors an idea of the timeline required for development of a drug for commercialization. The company recently won a battle related to patent protection for its MS drug Gilenya. The drug generated $738 million in revenue in Q2, and the judgment protects it from generic competition through 2027. Another reason to consider […]

Novartis AG (ADR) (NYSE:NVS) Heffx Trading Outlook

Novartis AG (ADR) (NYSE:NVS) Heffx Trading Outlook

Novartis AG (ADR) (NYSE:NVS) Heffx Trading Outlook Overall, the bias in prices is: Upwards. Short term: Prices are stalling. Intermediate term: Prices are ranging. The projected upper bound is: 83.51. The projected lower bound is: 79.43. The projected closing price is: 81.47. Candlesticks A white body occurred (because prices closed higher than they opened). During […]